These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 27796148)

  • 1. The potential use of urine cell free DNA as a marker for cancer.
    Salvi S; Martignano F; Molinari C; Gurioli G; Calistri D; De Giorgi U; Conteduca V; Casadio V
    Expert Rev Mol Diagn; 2016 Dec; 16(12):1283-1290. PubMed ID: 27796148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA-Methylation-Based Detection of Urological Cancer in Urine: Overview of Biomarkers and Considerations on Biomarker Design, Source of DNA, and Detection Technologies.
    Larsen LK; Lind GE; Guldberg P; Dahl C
    Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liquid biopsy: a step forward towards precision medicine in urologic malignancies.
    Di Meo A; Bartlett J; Cheng Y; Pasic MD; Yousef GM
    Mol Cancer; 2017 Apr; 16(1):80. PubMed ID: 28410618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The study of DNA methylation in urological cancer: present and future.
    Andrés G; Ashour N; Sánchez-Chapado M; Ropero S; Angulo JC
    Actas Urol Esp; 2013 Jun; 37(6):368-75. PubMed ID: 23643196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid biopsy in germ cell tumors: biology and clinical management.
    Chovanec M; Kalavska K; Mego M; Cheng L
    Expert Rev Mol Diagn; 2020 Feb; 20(2):187-194. PubMed ID: 31652083
    [No Abstract]   [Full Text] [Related]  

  • 6. Liquid biopsy in the clinical management of bladder cancer: current status and future developments.
    Kouba E; Lopez-Beltran A; Montironi R; Massari F; Huang K; Santoni M; Chovanec M; Cheng M; Scarpelli M; Zhang J; Cimadamore A; Cheng L
    Expert Rev Mol Diagn; 2020 Feb; 20(2):255-264. PubMed ID: 31608720
    [No Abstract]   [Full Text] [Related]  

  • 7. Urinary Cell-Free DNA: Potential and Applications.
    Salvi S; Casadio V
    Methods Mol Biol; 2019; 1909():201-209. PubMed ID: 30580433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary Biomarkers in Tumors: An Overview.
    Cimmino I; Bravaccini S; Cerchione C
    Methods Mol Biol; 2021; 2292():3-15. PubMed ID: 33651347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria.
    Xu Y; Kim YH; Jeong P; Piao XM; Byun YJ; Kang HW; Kim WT; Lee JY; Kim IY; Moon SK; Choi YH; Yun SJ; Kim WJ
    Urol Oncol; 2019 Jan; 37(1):86-96. PubMed ID: 30446454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical utility of molecular genetic cancer profiling.
    Joseph L
    Expert Rev Mol Diagn; 2016 Aug; 16(8):827-38. PubMed ID: 27253039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA alterations in body fluids as molecular tumor markers for urological malignancies.
    Goessl C; Müller M; Straub B; Miller K
    Eur Urol; 2002 Jun; 41(6):668-76. PubMed ID: 12074786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic biomarkers in the blood of patients with urological malignancies.
    Ellinger J; Müller SC; Dietrich D
    Expert Rev Mol Diagn; 2015 Apr; 15(4):505-16. PubMed ID: 25719388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential use of cell-free-circulating-tumor DNA as a biomarker for prostate cancer.
    He WS; Bishop KS
    Expert Rev Mol Diagn; 2016 Aug; 16(8):839-52. PubMed ID: 27254598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Circulating cell-free serum DNA: significance as a new biomarker for urological malignancies].
    Ellinger J; von Rücker A; Bastian PJ; Müller SC
    Urologe A; 2010 Sep; 49(9):1131-2, 1134. PubMed ID: 20628864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Circulating Cell-Free DNA in Cancers.
    Aarthy R; Mani S; Velusami S; Sundarsingh S; Rajkumar T
    Mol Diagn Ther; 2015 Dec; 19(6):339-50. PubMed ID: 26400814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA methylation signatures in circulating cell-free DNA as biomarkers for the early detection of cancer.
    Wang J; Han X; Sun Y
    Sci China Life Sci; 2017 Apr; 60(4):356-362. PubMed ID: 28063009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Molecular diagnostics in urologic oncology. Detection of nucleic acids in urine samples].
    Müller M; Goessl C; Krause H; Miller K
    Urologe A; 2003 May; 42(5):660-8. PubMed ID: 12750801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating biomarkers to guide systemic therapy for urothelial carcinoma.
    Abbosh PH; Rosenberg JE; Plimack ER
    Urol Oncol; 2016 Nov; 34(11):502-509. PubMed ID: 27751785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New method to preserve the original proportion and integrity of urinary cell-free DNA.
    Li P; Ning J; Luo X; Du H; Zhang Q; Zhou G; Du Q; Ou Z; Wang L; Wang Y
    J Clin Lab Anal; 2019 Feb; 33(2):e22668. PubMed ID: 30175467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer.
    Birkenkamp-Demtröder K; Nordentoft I; Christensen E; Høyer S; Reinert T; Vang S; Borre M; Agerbæk M; Jensen JB; Ørntoft TF; Dyrskjøt L
    Eur Urol; 2016 Jul; 70(1):75-82. PubMed ID: 26803478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.